Interleukin-1, neuroinflammation, and Alzheimer's disease

被引:290
作者
Mrak, RE [1 ]
Griffin, WST
机构
[1] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA
[3] Dept Vet Affairs Med Ctr, Little Rock, AR 72205 USA
关键词
A beta plaques; A beta precursor protein; aging; Alzheimer's disease; astrocytes; Down's syndrome; head trauma; IL-1; microglia; neuritic plaques; S100B;
D O I
10.1016/S0197-4580(01)00287-1
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Interleukin-1 (IL-1)-1) is a pluripotent immunomodulatory cytokine that has an initiating role in cellular and humoral immunity in the periphery. IL-1 is overexpressed in Alzheimer brain, and this overexpression is directly related to plaque formation and progression, nonsensical growth of dystrophic neurites, and neuronal overexpression of acetylcholinesterase. IL-1 has a number of actions relevant to Alzheimer's disease, including excessive expression of neuronal Ap precursor protein and other plaque-associated proteins, and induction of astrocyte activation and astrocytic overexpression of S100B. These latter events may be related to the overgrowth of dystrophic neurites in neuritic plaques, a necessary event for conversion of diffuse A beta deposits into the neuritic amyloid plaques diagnostic of Alzheimer's disease. Four new genetic studies underscore the relevance of IL-1 to Alzheimer pathogenesis, showing that homozygosity of a specific polymorphism in the IL-1A gene at least triples Alzheimer risk, especially for an earlier age of onset and in combination with homozygosity for another polymorphism in the IL-1B gene. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:903 / 908
页数:6
相关论文
共 73 条
  • [1] A randomized controlled trial of prednisone in Alzheimer's disease
    Aisen, PS
    Davis, KL
    Berg, JD
    Schafer, K
    Campbell, K
    Thomas, RG
    Weiner, MF
    Farlow, MR
    Sano, M
    Grundman, M
    Thal, LJ
    [J]. NEUROLOGY, 2000, 54 (03) : 588 - 593
  • [2] DO NONSTEROIDAL ANTIINFLAMMATORY DRUGS DECREASE THE RISK FOR ALZHEIMERS-DISEASE - THE ROTTERDAM STUDY
    ANDERSEN, K
    LAUNER, LJ
    OTT, A
    HOES, AW
    BRETELER, MMB
    HOFMAN, A
    [J]. NEUROLOGY, 1995, 45 (08) : 1441 - 1445
  • [3] [Anonymous], CYTOKINE
  • [4] AURON PE, 1994, EUR CYTOKINE NETW, V5, P573
  • [5] Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
    Barger, SW
    Harmon, AD
    [J]. NATURE, 1997, 388 (6645) : 878 - 881
  • [6] BARGER SW, 1992, J BIOL CHEM, V267, P9689
  • [7] Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies
    Bertram, L
    Blacker, D
    Crystal, A
    Mullin, K
    Keeney, D
    Jones, J
    Basu, S
    Yhu, S
    Guénette, S
    McInnis, M
    Go, R
    Tanzi, R
    [J]. EXPERIMENTAL GERONTOLOGY, 2000, 35 (9-10) : 1353 - 1361
  • [8] DELAYED-ONSET OF ALZHEIMERS-DISEASE WITH NONSTEROIDAL ANTIINFLAMMATORY AND HISTAMINE-H2 BLOCKING-DRUGS
    BREITNER, JCS
    WELSH, KA
    HELMS, MJ
    GASKELL, PC
    GAU, BA
    ROSES, AD
    PERICAKVANCE, MA
    SAUNDERS, AM
    [J]. NEUROBIOLOGY OF AGING, 1995, 16 (04) : 523 - 530
  • [9] INVERSE ASSOCIATION OF ANTIINFLAMMATORY TREATMENTS AND ALZHEIMERS-DISEASE - INITIAL RESULTS OF A COTWIN CONTROL STUDY
    BREITNER, JCS
    GAU, BA
    WELSH, KA
    PLASSMAN, BL
    MCDONALD, WM
    HELMS, MJ
    ANTHONY, JC
    [J]. NEUROLOGY, 1994, 44 (02) : 227 - 232
  • [10] CHOLINERGIC AGONISTS AND INTERLEUKIN-1 REGULATE PROCESSING AND SECRETION OF THE ALZHEIMER BETA/A4 AMYLOID PROTEIN-PRECURSOR
    BUXBAUM, JD
    OISHI, M
    CHEN, HI
    PINKASKRAMARSKI, R
    JAFFE, EA
    GANDY, SE
    GREENGARD, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) : 10075 - 10078